E. Jane Macaskill

776 total citations
18 papers, 533 citations indexed

About

E. Jane Macaskill is a scholar working on Genetics, Cancer Research and Molecular Biology. According to data from OpenAlex, E. Jane Macaskill has authored 18 papers receiving a total of 533 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 8 papers in Cancer Research and 5 papers in Molecular Biology. Recurrent topics in E. Jane Macaskill's work include Estrogen and related hormone effects (9 papers), Breast Cancer Treatment Studies (8 papers) and Advanced Breast Cancer Therapies (3 papers). E. Jane Macaskill is often cited by papers focused on Estrogen and related hormone effects (9 papers), Breast Cancer Treatment Studies (8 papers) and Advanced Breast Cancer Therapies (3 papers). E. Jane Macaskill collaborates with scholars based in United Kingdom and Switzerland. E. Jane Macaskill's co-authors include J. Michael Dixon, Lorna Renshaw, Juliette Murray, Oliver Young, David Cameron, Elizabeth Folkerd, Mitch Dowsett, J. Michael Dixon, John M.S. Bartlett and Vicky S. Sabine and has published in prestigious journals such as Journal of Clinical Oncology, Molecular Cancer and European Journal of Cancer.

In The Last Decade

E. Jane Macaskill

18 papers receiving 517 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Jane Macaskill United Kingdom 12 329 244 232 133 130 18 533
Oliver Young United Kingdom 10 351 1.1× 298 1.2× 311 1.3× 145 1.1× 106 0.8× 17 578
Juliette Murray United Kingdom 11 312 0.9× 276 1.1× 275 1.2× 137 1.0× 90 0.7× 27 532
Patricia Farmer Canada 7 381 1.2× 271 1.1× 398 1.7× 148 1.1× 102 0.8× 10 744
Catherine Harper‐Wynne United Kingdom 13 549 1.7× 360 1.5× 381 1.6× 183 1.4× 264 2.0× 45 876
Domen Ribnikar Canada 11 291 0.9× 199 0.8× 104 0.4× 97 0.7× 151 1.2× 31 470
Jan Smeets Netherlands 7 261 0.8× 218 0.9× 282 1.2× 47 0.4× 110 0.8× 8 421
Mauro Porpiglia Italy 11 456 1.4× 449 1.8× 564 2.4× 97 0.7× 124 1.0× 27 813
G. Gademann Germany 5 442 1.3× 395 1.6× 517 2.2× 61 0.5× 129 1.0× 14 733
Barbara Walley United States 13 436 1.3× 391 1.6× 249 1.1× 62 0.5× 186 1.4× 24 683
C. I. Li United States 6 305 0.9× 176 0.7× 113 0.5× 74 0.6× 44 0.3× 7 439

Countries citing papers authored by E. Jane Macaskill

Since Specialization
Citations

This map shows the geographic impact of E. Jane Macaskill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Jane Macaskill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Jane Macaskill more than expected).

Fields of papers citing papers by E. Jane Macaskill

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Jane Macaskill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Jane Macaskill. The network helps show where E. Jane Macaskill may publish in the future.

Co-authorship network of co-authors of E. Jane Macaskill

This figure shows the co-authorship network connecting the top 25 collaborators of E. Jane Macaskill. A scholar is included among the top collaborators of E. Jane Macaskill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Jane Macaskill. E. Jane Macaskill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Cookson, Victoria, Nicola Ingram, Brijesh Madhok, et al.. (2011). Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer. Molecular Cancer. 10(1). 19–19. 23 indexed citations
2.
Dixon, J. Michael, Lorna Renshaw, C. Langridge, et al.. (2010). Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability. Breast Cancer Research and Treatment. 125(3). 741–749. 14 indexed citations
3.
Macaskill, E. Jane, John M.S. Bartlett, Vicky S. Sabine, et al.. (2010). The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study. Breast Cancer Research and Treatment. 128(3). 725–734. 40 indexed citations
4.
Sabine, Vicky S., Andrew H. Sims, E. Jane Macaskill, et al.. (2010). Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer. Breast Cancer Research and Treatment. 122(2). 419–428. 37 indexed citations
5.
Kitchen, Robert R., Vicky S. Sabine, Andrew H. Sims, et al.. (2010). Correcting for intra-experiment variation in Illumina BeadChip data is necessary to generate robust gene-expression profiles. BMC Genomics. 11(1). 134–134. 26 indexed citations
6.
Renshaw, Lorna, Linda Williams, Oliver Young, et al.. (2009). A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment. 119(3). 643–651. 24 indexed citations
7.
Sims, Andrew H., Vicky S. Sabine, E. Jane Macaskill, et al.. (2009). GENE EXPRESSION PROFILING OF ER-POSITIVE BREAST TUMOURS FROM POST-MENOPAUSAL WOMEN TREATED WITH NEOADJUVANT RAD001. 20. 52–52. 1 indexed citations
8.
Dixon, J. Michael, Lorna Renshaw, E. Jane Macaskill, et al.. (2008). Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Research and Treatment. 113(1). 145–151. 80 indexed citations
9.
Dixon, J. Michael, Lorna Renshaw, Oliver Young, et al.. (2008). Letrozole Suppresses Plasma Estradiol and Estrone Sulphate More Completely Than Anastrozole in Postmenopausal Women With Breast Cancer. Journal of Clinical Oncology. 26(10). 1671–1676. 125 indexed citations
10.
Dixon, J. Michael, Dana Faratian, Sharon White, et al.. (2007). DCIS and aromatase inhibitors. The Journal of Steroid Biochemistry and Molecular Biology. 106(1-5). 173–179. 6 indexed citations
11.
Renshaw, Lorna, et al.. (2007). Effects of fulvestrant 750 mg in premenopausal women with oestrogen-receptor-positive primary breast cancer. European Journal of Cancer. 44(3). 391–399. 55 indexed citations
12.
Renshaw, Lorna, E. Jane Macaskill, Juliette Murray, et al.. (2007). P132 Factors predicting survival after neoadjuvant therapy with aromatase inhibitors. The Breast. 16. S50–S51. 2 indexed citations
13.
Dixon, J. Michael & E. Jane Macaskill. (2007). For the use of ultrasound by surgeons. 10(3). 1–3. 3 indexed citations
14.
Dixon, J. Michael, E. Jane Macaskill, Lorna Renshaw, et al.. (2007). P155 Anastrozole and letrozole – an investigation and comparison of quality of life, tolerability and morbidity. The Breast. 16. S57–S57. 1 indexed citations
15.
Macaskill, E. Jane, et al.. (2006). Surgeons’ views on multi-disciplinary breast meetings. European Journal of Cancer. 42(7). 905–908. 44 indexed citations
16.
Macaskill, E. Jane, Lorna Renshaw, & J. Michael Dixon. (2006). Neoadjuvant Use of Hormonal Therapy in Elderly Patients with Early or Locally Advanced Hormone Receptor–Positive Breast Cancer. The Oncologist. 11(10). 1081–1088. 24 indexed citations
17.
Dixon, J. Michael, Lorna Renshaw, Juliette Murray, et al.. (2006). Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer. Journal of Clinical Oncology. 24(18_suppl). 552–552. 22 indexed citations
18.
Dixon, J. Michael, Lorna Renshaw, Juliette Murray, et al.. (2005). Surgical issues surrounding use of aromatase inhibitors. The Journal of Steroid Biochemistry and Molecular Biology. 95(1-5). 97–103. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Oliver Young Breakdown of academic impact, for papers by Juliette Murray Breakdown of academic impact, for papers by Patricia Farmer Breakdown of academic impact, for papers by Catherine Harper‐Wynne Breakdown of academic impact, for papers by Domen Ribnikar Breakdown of academic impact, for papers by Jan Smeets Breakdown of academic impact, for papers by Mauro Porpiglia Breakdown of academic impact, for papers by G. Gademann Breakdown of academic impact, for papers by Barbara Walley Breakdown of academic impact, for papers by C. I. Li
Rankless by CCL
2026